Exogenous steroid replacement in a pediatric patient with adrenocortical carcinoma receiving mitotane

Pediatr Blood Cancer. 2024 Aug;71(8):e31072. doi: 10.1002/pbc.31072. Epub 2024 May 12.

Authors

Catherine E Martin¹, Alexis K Kuhn¹, Kaitlin N Leopold², Ana L Creo², Peter J Schoettler³, Wendy A Allen-Rhoades³

Affiliations

¹ Department of Pharmacy - Ambulatory Service, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
³ Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 38736192
DOI: 10.1002/pbc.31072

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Adrenal Cortex Neoplasms* / drug therapy
Adrenal Cortex Neoplasms* / pathology
Adrenocortical Carcinoma* / drug therapy
Adrenocortical Carcinoma* / pathology
Antineoplastic Agents, Hormonal* / administration & dosage
Antineoplastic Agents, Hormonal* / therapeutic use
Female
Hormone Replacement Therapy
Humans
Mitotane* / therapeutic use

Substances

Antineoplastic Agents, Hormonal
Mitotane